Key result
Extended-release niacin added to statin therapy did not increase the rate of internal carotid artery wall volume regression compared to statin therapy alone.
Why the study?
Does extended release niacin added to statin therapy improve the regression of carotid atherosclerosis in older patients with established atherosclerosis?
RCT (n=145)
Double-blind
1:1
No
Does extended release niacin added to statin therapy improve the regression of carotid atherosclerosis in older patients with established atherosclerosis?
Adding extended-release niacin to statin therapy does not provide additional benefit for the regression of carotid atherosclerosis in older patients.
Answers are grounded in this paper and cite their sources.
Niacin adds no plaque regression benefit beyond statins in older patients with atherosclerosis; reinforces statin monotherapy and challenges surrogate endpoint optimism.
OBJECTIVE: To evaluate the benefit of niacin in addition to statin therapy on plaque regression among older individuals with established atherosclerosis. DESIGN: Randomised, controlled, double-blind clinical trial. SETTING: University outpatient center. PATIENTS: 145 patients older than 65 years, half of them older than 75 years of age, with established atherosclerosis were enrolled. INTERVENTIONS: Participants received either extended release niacin (1500 mg daily) or placebo in addition to statin therapy to reach their National Cholesterol Education Program-defined low density lipoprotein (LDL) cholesterol target. MAIN OUTCOME MEASURES: The primary endpoint was reduction in the wall volume of the internal carotid artery (ICA) measured by MRI. RESULTS: After 18 months, high density lipoprotein cholesterol was higher with statins plus niacin compared with statins alone (1.6 ± 0.4 vs 1.4 ± 0.4 mmol/L p<0.001). Both groups had significant decreases in the main outcome measure of ICA wall volume, which regressed at 0.5%/month (SEM 0.2, p=0.004) in the statins plus placebo group and at 0.7%/month in the statins plus niacin group (SEM 0.2, p<0.001). There was no difference in the rate of regression between groups (p=0.49). CONCLUSIONS: Treatment with statin therapy to presently recommended LDL levels, with or without niacin, resulted in significant atherosclerosis reduction.
No takes yet. Share an insight, caveat, or question.
Sibley et al. (2013) conducted an RCT in Established atherosclerosis (n=145). Extended release niacin vs. Placebo was evaluated on Change in internal carotid artery (ICA) wall volume over 18 months (p=0.49). Extended-release niacin added to statin therapy did not increase the rate of internal carotid artery wall volume regression compared to statin therapy alone.
Synapse has enriched 10 related papers. Consider them for comparative context: